Breast Cancer Mortality Rates Down

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--The breast cancer death rate in American women has declined steadily in the 1990s, suggesting that improved breast cancer management from early detection to treatment is having a beneficial effect, the National Cancer Institute reports.

WASHINGTON--The breast cancer death rate in American women hasdeclined steadily in the 1990s, suggesting that improved breastcancer management from early detection to treatment is havinga beneficial effect, the National Cancer Institute reports.

From 1989 to 1993, age-adjusted mortality rates fell approximately6% in white women and rose about 1% in black women. This is animprovement over 1980 to 1989, when rates increased by 3% in whitewomen and 16% in black women.

The report attributed the decline in mortality only partly tomammography screening, stating that "further study is requiredto determine the relative contribution of early detection andimproved treatment."

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content